Literature DB >> 16541425

Normal and prostate cancer cells display distinct molecular profiles of alpha-tubulin posttranslational modifications.

Karel Soucek1, Andrés Kamaid, Anh D Phung, Lukás Kubala, J Chloë Bulinski, Richart W Harper, Jason P Eiserich.   

Abstract

BACKGROUND: Multiple diverse posttranslational modifications of alpha-tubulin such as detyrosination, further cleavage of the penultimate glutamate residue (Delta2-tubulin), acetylation, and polyglutamylation increase the structural and functional diversity of microtubules.
METHODS: Herein, we characterized the molecular profile of alpha-tubulin posttranslational modifications in normal human prostate epithelial cells (PrEC), immortalized normal prostate epithelial cells (PZ-HPV-7), androgen-dependent prostate cancer cells (LNCaP), transitional androgen-independent prostate cancer cells (LNCaP-cds and CWR22Rv1), and androgen-independent prostate cancer cells (PC3).
RESULTS: Compared to PrEC and PZ-HPV-7 cells, all cancer cells exhibited elevated levels of detyrosinated and polyglutamylated alpha-tubulin, that was paralleled by decreased protein levels of tubulin tyrosine ligase (TTL). In contrast, PrEC and PZ-HPV-7 cells expressed markedly higher levels of Delta2-tubulin. Whereas alpha-tubulin acetylation levels were generally equivalent in all the cell lines, PC3 cells did not display detectable levels of Ac-tubulin.
CONCLUSION: These data may reveal novel biomarkers of prostate cancer and new therapeutic targets. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16541425     DOI: 10.1002/pros.20416

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  34 in total

1.  Epithelial-to-mesenchymal transition promotes tubulin detyrosination and microtentacles that enhance endothelial engagement.

Authors:  Rebecca A Whipple; Michael A Matrone; Edward H Cho; Eric M Balzer; Michele I Vitolo; Jennifer R Yoon; Olga B Ioffe; Kimberly C Tuttle; Jing Yang; Stuart S Martin
Journal:  Cancer Res       Date:  2010-10-05       Impact factor: 12.701

Review 2.  Post-translational regulation of the microtubule cytoskeleton: mechanisms and functions.

Authors:  Carsten Janke; Jeannette Chloë Bulinski
Journal:  Nat Rev Mol Cell Biol       Date:  2011-11-16       Impact factor: 94.444

Review 3.  Dietary manipulation of histone structure and function.

Authors:  Emily Ho; Roderick H Dashwood
Journal:  World Rev Nutr Diet       Date:  2010-04-30       Impact factor: 0.575

Review 4.  Tubulin modifications and their cellular functions.

Authors:  Jennetta W Hammond; Dawen Cai; Kristen J Verhey
Journal:  Curr Opin Cell Biol       Date:  2008-01-15       Impact factor: 8.382

5.  The synovial sarcoma SYT-SSX2 oncogene remodels the cytoskeleton through activation of the ephrin pathway.

Authors:  Roy Barco; Laura B Hunt; Andrea L Frump; Christina B Garcia; Andrew Benesh; Robert L Caldwell; Josiane E Eid
Journal:  Mol Biol Cell       Date:  2007-08-08       Impact factor: 4.138

Review 6.  Targeting mitotic pathways for endocrine-related cancer therapeutics.

Authors:  Shivangi Agarwal; Dileep Varma
Journal:  Endocr Relat Cancer       Date:  2017-06-14       Impact factor: 5.678

7.  Dietary manipulation of histone structure and function.

Authors:  Emily Ho; Roderick H Dashwood
Journal:  J Nutrigenet Nutrigenomics       Date:  2011-04-06

8.  Molecular interactions between tubulin tails and glutamylases reveal determinants of glutamylation patterns.

Authors:  Kathiresan Natarajan; Sudarshan Gadadhar; Judith Souphron; Maria M Magiera; Carsten Janke
Journal:  EMBO Rep       Date:  2017-05-08       Impact factor: 8.807

Review 9.  The chemical complexity of cellular microtubules: tubulin post-translational modification enzymes and their roles in tuning microtubule functions.

Authors:  Christopher P Garnham; Antonina Roll-Mecak
Journal:  Cytoskeleton (Hoboken)       Date:  2012-04-26

10.  The roles of beta-tubulin mutations and isotype expression in acquired drug resistance.

Authors:  J Torin Huzil; Ke Chen; Lukasz Kurgan; Jack A Tuszynski
Journal:  Cancer Inform       Date:  2007-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.